Replies to post #418607 on Amarin Corp Plc (AMRN)

[JRoon71]

ORB, you are 100% right. But how many people are getting all of those biomarkers tested and tracking them routinely?

When I get my basic lipid panel and CMP done at Quest each year for my physical, none of those markers are tested. I have to specifically request them as separate tests. And if doctors are not ordering those tests, 99% of people don't know to get them tested.

I will say that there is more recent awareness of Lp(a), hsCRP, etc. But this is a rather recent phenomenon. And if the DOCTORS do not believe in Vascepa, then they are certainly not selling patients on it.

This is not a failure of Vascepa, it's a failure of Amarin and their lack of PR/marketing efforts.

[Tatsumaki]

If it's not on the drug label, it's not being promoted. Statins were successful because high cholesterol was advertised as a problem leading to CVD issues and the label lowered cholesterol. Lovaza was successful because high Trigs was advertised as a problem leading to CVD issues and it lowered Trigs.

hsCRP, Lp(a), LDL size, oxidation markers, etc... etc... etc... until commercials show up on TV and website popups telling people those markers are important and if out of a good range they are at risk of a heart attack or any other disease, and Vascepa can them in line, none of them matter to the market.

The problem has to be sold first. Then the drug marketed to fix it.